Entrada Therapeutics Inc. provided an update on its expanding pipeline of intracellular therapeutics, highlighting several clinical-stage programs targeting diseases with significant unmet medical needs. The company’s Duchenne muscular dystrophy (DMD) franchise includes multiple candidates, with clinical data expected for ENTR-601-44 and ENTR-601-45 in 2026. Additionally, ENTR-601-50 has received authorization for a Phase 1/2 study in the U.K., with a European Union filing anticipated later in the year. The myotonic dystrophy type 1 (DM1) program, partnered with Vertex, has progressed to the multiple ascending dose phase, with completion of enrollment and dosing expected in the first half of 2026. The company is utilizing ex-U.S. clinical data to inform discussions with regulatory agencies regarding potential accelerated approval pathways and plans to initiate global registrational studies for broader approval. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.